June 2nd 2025
MedNews Week hosts speak with 5 key opinion leaders at ASCO 2025 about the top data highlights of the day.
June 1st 2025
Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.
Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.
Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.
First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.
BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.
Elraglusib plus gemcitabine/nab-paclitaxel displayed an OS benefit vs chemotherapy alone in untreated metastatic pancreatic ductal adenocarcinoma.
Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.
Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.
Sacituzumab tirumotecan showed statistically significant improvements in responses and survival vs docetaxel alone in advanced EGFR-mutant NSCLC.
Patritumab deruxtecan did not improve OS vs platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic NSCLC.
Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.
Savolitinib plus osimertinib was safe and effective in patients with EGFR-mutated, MET-amplified advanced NSCLC after disease progression on an EGFR TKI.
Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.
CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.
David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.
The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.
Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.